CZ303143B6 - Zpusob výroby arylethanolaminových derivátu s antiobezitními a antidiabetickými vlastnostmi - Google Patents

Zpusob výroby arylethanolaminových derivátu s antiobezitními a antidiabetickými vlastnostmi Download PDF

Info

Publication number
CZ303143B6
CZ303143B6 CZ20022017A CZ20022017A CZ303143B6 CZ 303143 B6 CZ303143 B6 CZ 303143B6 CZ 20022017 A CZ20022017 A CZ 20022017A CZ 20022017 A CZ20022017 A CZ 20022017A CZ 303143 B6 CZ303143 B6 CZ 303143B6
Authority
CZ
Czechia
Prior art keywords
formula
compound
alkyl
amino
hydrogen
Prior art date
Application number
CZ20022017A
Other languages
Czech (cs)
English (en)
Other versions
CZ20022017A3 (cs
Inventor
Maxwell Lawrence@Ronnie
Millar@Alan
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CZ20022017A3 publication Critical patent/CZ20022017A3/cs
Publication of CZ303143B6 publication Critical patent/CZ303143B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
CZ20022017A 1999-12-11 2000-12-08 Zpusob výroby arylethanolaminových derivátu s antiobezitními a antidiabetickými vlastnostmi CZ303143B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process

Publications (2)

Publication Number Publication Date
CZ20022017A3 CZ20022017A3 (cs) 2003-01-15
CZ303143B6 true CZ303143B6 (cs) 2012-05-02

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20022017A CZ303143B6 (cs) 1999-12-11 2000-12-08 Zpusob výroby arylethanolaminových derivátu s antiobezitními a antidiabetickými vlastnostmi

Country Status (23)

Country Link
US (1) US6548523B2 (cg-RX-API-DMAC10.html)
EP (1) EP1235788B1 (cg-RX-API-DMAC10.html)
JP (1) JP4903964B2 (cg-RX-API-DMAC10.html)
KR (1) KR100683614B1 (cg-RX-API-DMAC10.html)
CN (1) CN1224609C (cg-RX-API-DMAC10.html)
AT (1) ATE292110T1 (cg-RX-API-DMAC10.html)
AU (1) AU769387B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0016187B1 (cg-RX-API-DMAC10.html)
CA (1) CA2394117C (cg-RX-API-DMAC10.html)
CZ (1) CZ303143B6 (cg-RX-API-DMAC10.html)
DE (1) DE60019157T2 (cg-RX-API-DMAC10.html)
ES (1) ES2236020T3 (cg-RX-API-DMAC10.html)
GB (1) GB9929297D0 (cg-RX-API-DMAC10.html)
HK (1) HK1045988B (cg-RX-API-DMAC10.html)
HU (1) HU229043B1 (cg-RX-API-DMAC10.html)
IL (1) IL149585A0 (cg-RX-API-DMAC10.html)
NO (1) NO323239B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ518795A (cg-RX-API-DMAC10.html)
PL (1) PL200540B1 (cg-RX-API-DMAC10.html)
PT (1) PT1235788E (cg-RX-API-DMAC10.html)
TR (1) TR200201528T2 (cg-RX-API-DMAC10.html)
WO (1) WO2001042195A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200204585B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
TW201338772A (zh) 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543662A2 (en) * 1991-11-20 1993-05-26 Sankyo Company Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
WO1997021666A1 (en) * 1995-12-08 1997-06-19 Glaxo Group Limited Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors
WO1999065877A1 (en) * 1998-06-13 1999-12-23 Glaxo Group Limited Therapeutic biaryl derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
SK16282000A3 (sk) * 1998-05-01 2001-05-10 Abbott Laboratories Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543662A2 (en) * 1991-11-20 1993-05-26 Sankyo Company Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
WO1997021666A1 (en) * 1995-12-08 1997-06-19 Glaxo Group Limited Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors
WO1999065877A1 (en) * 1998-06-13 1999-12-23 Glaxo Group Limited Therapeutic biaryl derivatives

Also Published As

Publication number Publication date
ES2236020T3 (es) 2005-07-16
NO20022758L (no) 2002-07-01
EP1235788A1 (en) 2002-09-04
KR20020061636A (ko) 2002-07-24
GB9929297D0 (en) 2000-02-02
WO2001042195A1 (en) 2001-06-14
HK1045988A1 (en) 2002-12-20
US6548523B2 (en) 2003-04-15
NZ518795A (en) 2004-02-27
CN1409700A (zh) 2003-04-09
HUP0203640A3 (en) 2003-08-28
JP4903964B2 (ja) 2012-03-28
PL200540B1 (pl) 2009-01-30
NO323239B1 (no) 2007-02-05
DE60019157D1 (de) 2005-05-04
KR100683614B1 (ko) 2007-02-16
AU769387B2 (en) 2004-01-22
PL356483A1 (en) 2004-06-28
PT1235788E (pt) 2005-08-31
CN1224609C (zh) 2005-10-26
IL149585A0 (en) 2002-11-10
HK1045988B (en) 2005-07-15
TR200201528T2 (tr) 2002-09-23
CA2394117C (en) 2011-10-04
HUP0203640A2 (hu) 2003-02-28
ZA200204585B (en) 2003-12-31
AU2191101A (en) 2001-06-18
EP1235788B1 (en) 2005-03-30
CA2394117A1 (en) 2001-06-14
ATE292110T1 (de) 2005-04-15
HU229043B1 (hu) 2013-07-29
JP2003516383A (ja) 2003-05-13
CZ20022017A3 (cs) 2003-01-15
NO20022758D0 (no) 2002-06-10
US20020198220A1 (en) 2002-12-26
BR0016187A (pt) 2002-08-13
BRPI0016187B1 (pt) 2016-08-02
DE60019157T2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
TWI230162B (en) Geranyl group-containing compounds
JPS5943459B2 (ja) N−アルキルピペリジン誘導体
JP2010515750A (ja) スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物
CA2696429A1 (en) Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
US20030232806A1 (en) Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
WO2024108670A1 (zh) 一种依度沙班关键中间体及其合成方法
KR100683614B1 (ko) 항-비만 및 항-당뇨 특성을 갖는 아릴에탄올아민 유도체의제조 방법
CN115894439B (zh) 一种靶向降解gpx4的protac嵌合体及其制备方法和应用
CN106458965A (zh) 杂芳基羧酸酯衍生物的制造方法及其制造中间体
JP3479511B2 (ja) マトリックスメタロプロテイナーゼ阻害薬の製造に有用なヒンダードスルホンアミド類のアルキル化方法
AU2002253815B2 (en) Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
JP2002540108A (ja) [S−(R*,S*)]−β−[[[1−[1−オキソ−3−(4−ピペリジニル)プロピル]−3−ピペリジニル]カルボニル]アミノ]−3−ピリジンプロパン酸及び誘導体を製造する方法
CA1052788A (fr) Procede d'obtention de nouveaux acetamides n-substitues et les composes ainsi obtenus
JPH05500214A (ja) ターシヤリーアルキルエステル類の新規な合成方法
IE832063L (en) 1-pyridyloxy-3-indolyalkylamino-2-propanols
CN111471041A (zh) 一种噁唑烷酮类抗菌药物中间体的合成方法
CN101906069A (zh) (s)-2-取代-(3’-乙酰基-2’-吡啶酮-1’-基)乙酸及其制备方法和应用
JP2717257B2 (ja) 光学活性化合物の製造法
WO2007074553A1 (ja) 立体選択的にストレッカー反応を進行させ得る触媒、およびそれを用いたα−アミノニトリル誘導体を立体選択的に製造するための方法
MXPA02005823A (en) Process for the preparation of arylethanolamine derivatives having an anti obesity and anti diabetic properties
TWI223647B (en) Crystalline polymorph of aminoethylphenoxyacetic acid derivative
KR0181215B1 (ko) N-치환 헤테로 화합물 및 이의 제조방법
BRPI0616906A2 (pt) método para a sìntese de compostos para a inibição de selectina e composição farmacêutica
JPH06145125A (ja) カルボキサミド誘導体
JP2013100279A (ja) マンデル酸アミド誘導体の製造方法及びその中間体

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20151208